Genetic polymorphisms in pre-microRNAs and risk of ischemic stroke in a Chinese population

Yun Liu1, Ying Ma, Bo Zhang

  • 1Department of Forensic Medicine, North Shichuan Medical College, Nanchong, 637000, People's Republic of China.

Insights

Single-nucleotide polymorphisms in microRNAs are linked to ischemic stroke risk. The hsa-mir-499/rs3746444 A/G polymorphism showed a significant association with increased ischemic stroke risk in the Chinese population.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Ischemic stroke is a complex disease influenced by genetic and environmental factors.
  • MicroRNAs play roles in various physiological processes, and single-nucleotide polymorphisms (SNPs) in pre-microRNAs can affect disease susceptibility.

Purpose of the Study:

  • To investigate the association between common polymorphisms in pre-microRNAs (hsa-mir-196-a2/rs11614913, hsa-mir-146a/rs2910164, and hsa-mir-499/rs3746444) and the risk of ischemic stroke in a Chinese population.

Main Methods:

  • Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to genotype three pre-microRNA SNPs.
  • The study included 296 ischemic stroke patients and 391 healthy controls from a Chinese population.

Main Results:

  • The hsa-mir-499/rs3746444 A/G polymorphism was significantly associated with an increased risk of ischemic stroke (OR = 1.509, P = 0.003).
  • Specific genotypes of rs3746444 (AA, AG, and AG+AA) showed increased risk in various genetic models.
  • No significant association was found for hsa-mir-196-a2/rs11614913 T/C and hsa-mir-146a/rs2910164 C/G polymorphisms with ischemic stroke risk.

Conclusions:

  • The hsa-mir-499/rs3746444 A/G polymorphism may contribute to the pathogenesis of ischemic stroke in the Chinese population.
  • Common genetic variations in pre-microRNAs can influence the risk of ischemic stroke.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.9K
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
196